Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3475766 in Dyslipidemia
NCT04052594Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2019
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3475766 in dyslipidemia (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. Started Sep 2019; status: completed.
02
Drugs
LY3475766
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT04052594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04052594.